FDA — authorised 28 October 2011
- Application: NDA022496
- Marketing authorisation holder: PACIRA PHARMS INC
- Local brand name: EXPAREL
- Indication: INJECTABLE, LIPOSOMAL — INJECTION
- Status: approved
🇺🇸 Abdominal wall block with liposomal bupivicaine in United States
FDA authorised Abdominal wall block with liposomal bupivicaine on 28 October 2011
Marketing authorisations
FDA
- Status: approved
Abdominal wall block with liposomal bupivicaine in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Abdominal wall block with liposomal bupivicaine approved in United States?
Yes. FDA authorised it on 28 October 2011; FDA has authorised it.
Who is the marketing authorisation holder for Abdominal wall block with liposomal bupivicaine in United States?
PACIRA PHARMS INC holds the US marketing authorisation.